Works matching IS 03407004 AND DT 2020 AND VI 69 AND IP 3

Results: 17

Acknowledgement to reviewers.

Published in:: Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 495, doi. 10.1007/s00262-020-02505-y
Publication type:: Article

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 493, doi. 10.1007/s00262-020-02489-9

By:

Su, Zhaoliang;
Ni, Ping;
She, Peng;
Liu, Yueqin;
Richard, Seidu A.;
Xu, Wenlin;
Zhu, Haitao;
Wang, Jia

Publication type:

Article

PCSK9 is a promising prognostic marker in patients with advanced NSCLC.

Published in:

2020

By:

Bonaventura, Aldo;
Grossi, Francesco;
Montecucco, Fabrizio

Publication type:

Letter

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 449, doi. 10.1007/s00262-020-02480-4

By:

Thomas, Remy;
Shaath, Hibah;
Naik, Adviti;
Toor, Salman M.;
Elkord, Eyad;
Decock, Julie

Publication type:

Article

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 477, doi. 10.1007/s00262-019-02466-x

By:

Boudewijns, Steve;
Bloemendal, Martine;
de Haas, Nienke;
Westdorp, Harm;
Bol, Kalijn F.;
Schreibelt, Gerty;
Aarntzen, Erik H. J. G.;
Lesterhuis, W. Joost;
Gorris, Mark A. J.;
Croockewit, Alexandra;
van der Woude, Lieke L.;
van Rossum, Michelle M.;
Welzen, Marieke;
de Goede, Anna;
Hato, Stanleyson V.;
van der Graaf, Winette T. A.;
Punt, Cornelis J. A.;
Koornstra, Rutger H. T.;
Gerritsen, Winald R.;
Figdor, Carl G.

Publication type:

Article

The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 465, doi. 10.1007/s00262-020-02479-x

By:

Quan, Hongzhi;
Shan, Zhongyan;
Liu, Ziyi;
Liu, Sixuan;
Yang, Liu;
Fang, Xiaodan;
Li, Kun;
Wang, Baisheng;
Deng, Zhiyuan;
Hu, Yanjia;
Yao, Zhigang;
Huang, Junhui;
Yu, Jianjun;
Xia, Kun;
Tang, Zhangui;
Fang, Liangjuan

Publication type:

Article

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 421, doi. 10.1007/s00262-019-02477-8

By:

Sarkar, Subhashis;
Chauhan, Sachin K. S.;
Daly, John;
Natoni, Alessandro;
Fairfield, Heather;
Henderson, Robert;
Nolan, Emma;
Swan, Dawn;
Hu, Jinsong;
Reagan, Michaela R.;
O'Dwyer, Michael

Publication type:

Article

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 435, doi. 10.1007/s00262-019-02472-z

By:

Bergenfelz, Caroline;
Roxå, Anna;
Mehmeti, Meliha;
Leandersson, Karin;
Larsson, Anna-Maria

Publication type:

Article

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 407, doi. 10.1007/s00262-019-02464-z

By:

Roussel, Mikael;
Lhomme, Faustine;
Roe, Caroline E.;
Bartkowiak, Todd;
Gravelle, Pauline;
Laurent, Camille;
Fest, Thierry;
Irish, Jonathan M.

Publication type:

Article

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 399, doi. 10.1007/s00262-019-02462-1

By:

Zhang, Guowei;
Cheng, Ruirui;
Wang, Huijuan;
Zhang, Yong;
Yan, Xiangtao;
Li, Peng;
Zhang, Mina;
Zhang, Xiaojuan;
Yang, Jinpo;
Niu, Yuanyuan;
Ma, Zhiyong

Publication type:

Article

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 325, doi. 10.1007/s00262-019-02461-2

By:

Patel, Akshay J.;
Richter, Alex;
Drayson, Mark T.;
Middleton, Gary W.

Publication type:

Article

Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 373, doi. 10.1007/s00262-019-02459-w

By:

Salamon, Pazit;
Mekori, Yoseph A.;
Shefler, Irit

Publication type:

Article

Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 355, doi. 10.1007/s00262-019-02458-x

By:

Bains, Simer J.;
Abrahamsson, Hanna;
Flatmark, Kjersti;
Dueland, Svein;
Hole, Knut H.;
Seierstad, Therese;
Redalen, Kathrine Røe;
Meltzer, Sebastian;
Ree, Anne Hansen

Publication type:

Article

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 383, doi. 10.1007/s00262-019-02456-z

By:

Battaglia, Alessandra;
Buzzonetti, Alexia;
Fossati, Marco;
Scambia, Giovanni;
Fattorossi, Andrea;
Madiyalakan, Madi R.;
Mahnke, Yolanda D.;
Nicodemus, Christopher

Publication type:

Article

The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 343, doi. 10.1007/s00262-019-02453-2

By:

Wilson, Brooke E.;
Routy, Bertrand;
Nagrial, Adnan;
Chin, Venessa T.

Publication type:

Article

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 365, doi. 10.1007/s00262-019-02452-3

By:

Ma, Junxun;
Sun, Danyang;
Wang, Jinliang;
Han, Chun;
Qian, Yuanyu;
Chen, Guangying;
Li, Xiaoyan;
Zhang, Juan;
Cui, Pengfei;
Du, Wushuang;
Wu, Zhaozhen;
Chen, Shixue;
Zheng, Xuan;
Yue, Zhichao;
Song, Jia;
Gao, Chan;
Cai, Shangli;
Hu, Yi

Publication type:

Article

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab.

Published in:

2020

By:

Li, Pengfei;
Che, Guowei

Publication type:

Letter